Matthieu Coutet

Partner, Sofinnova Partners - Biovelocita Strategy

Matthieu Coutet is a Partner in the Sofinnova Biovelocita strategy. He has nearly 20 years of experience in venture capital and operations, having spent a decade of those in technology transfer as the head of the New Venture department at Inserm Transfert and the Managing Partner of Inserm Transfert Initiative. In this role, Matthieu completed 14 seed-stage investments in companies emerging from academic research.

Matthieu later served as Vice President of Operations and Business Development for two French biotechnology startups, TherAchon (acquired by Pfizer) and Annapurna Therapeutics (merged with Adverum Biotechnology). He is a member of the Board of France Biotech.

In 2016, he co-founded AdBio Partners, raising funds dedicated to start-up investments across Europe. With AdBio Partners, he co-founded six biotechnology companies, identifying them while they were still laboratory research projects and securing financing.

Over his years of experience managing seed-stage investments, implementing financial and operational strategies, Matthieu has built up a strong network of researchers, entrepreneurs, and technology transfer professionals with whom he has established partnerships.

"I saw joining Sofinnova Partners as an opportunity to work with a team deeply experienced in science, entrepreneurship, and investment," he said. "Scaling up early-stage companies from academic concepts to industrial development provides a great sense of accomplishment."

Matthieu is a graduate of ESIEE Management and holds a professional certification in market-related activities.

"I saw joining Sofinnova Partners as an opportunity to work with a team deeply experienced in science, entrepreneurship, and investment. Scaling up early-stage companies from academic concepts to industrial development provides a great sense of accomplishment."

Sector

Biopharmaceuticals

Join our mailing list

Keep up to date with our latest news.

Required
Thanks for submitting the form. You are now subscribed to Sofinnova Partners news alerts.An error happened. Please try again later.